Publication date: Sep 20, 2018
Oncolytic viruses represent a unique type of agents that combine self-amplification, lytic and immunostimulatory properties against tumors. A local and locoregional clinical benefit has been demonstrated upon intratumoral injections of an oncolytic herpes virus in melanoma patients, leading to its approval in USA and Europe for patients without visceral disease (up to stage IVM1a). However, in order to debulk and change the local immunosuppressive environment of tumors that cannot be injected directly, oncolyitc viruses need to be administered systemically. Among different viruses, adenovirus has been extensively used in clinical trials but with few evidences of activity upon systemic administration. Preclinical efficacy of a single intravenous administration of our oncolytic adenovirus ICOVIR5, an adenovirus type 5 responsive to the pRB pathway commonly deregulated in tumors, led us to use this virus in a dose-escalation phase I trial in metastatic melanoma patients. The results in 12 patients, treated with a single infusion of a dose up to 1E13 viral particles, show that ICOVIR5 can reach melanoma metastases upon a single intravenous administration but fails to induce tumor regressions. These results support the systemic administration of armed oncolytic viruses to treat disseminated cancer.
Garcia, M., Moreno, R., Gil, M., Cascallo, M., de Olza, M.O., Cuadra, C., Piulat, J.M., , Navarro, Domenech, M., Alemany, R., and Salazar, R. A phase I trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. 20103. 2018 Hum Gene Ther.
Please signin to view all article content and metadata.